Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 9/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | CTDSP1 | Q9GZU7 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | PTPN7 | P35236 | 3/20 | 1.00 |
| ▸ | APEX1 | P27695 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | GAPDH | P04406 | 2/20 | 1.00 |
| ▸ | NR4A1 | P22736 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | GLS | O94925 | 6/20 | 0.88 |
| ▸ | F2 | P00734 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | RECQL | P46063 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14986950 | 0.94 | GLS (1.00) | POLBL3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL16306830 | 0.92 | GLS (0.95) | POLBL3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL14987287 | 0.83 | GLS (1.00) | POLBL3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL15043807 | 0.81 | GLS (1.00) | POLBL3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL21368571 | 0.80 | GLS (0.77) | POLBL3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL2116109 | 0.79 | GLS (0.88) | POLBL3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL14987500 | 0.79 | GLS (1.00) | GLS | |
| SCHEMBL14987507 | 0.79 | GLS (1.00) | GLS | |
| SCHEMBL15724977 | 0.78 | GLS (0.70) | POLBL3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL17172556 | 0.78 | GLS (0.70) | POLBL3MBTL1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | claimed |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2012-04-19 | — | — | US | disclosed |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2012-04-19 | — | — | US | disclosed |
| US-20090118135-A1 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS | THE BURNHAM INSTITUTE (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090118135-A1 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS | THE BURNHAM INSTITUTE (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | disclosed |
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | MCL1, AS3MT, MYADM | POLB 819/4885L3MBTL1 1464/4885MEN1 1901/4885 |
| US-20090118135-A1 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS | BCL2, BAX, BAD | POLB 1539/4885L3MBTL1 141/4885MEN1 4323/4885 |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | MCL1, AS3MT, MYADM | POLB 819/4885L3MBTL1 1464/4885MEN1 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.